Press releases
- Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI
- Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
- Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
- Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
- Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
- Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
- Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
- Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery
- Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
- Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
More ▼
Key statistics
On Thursday, QUEST DIAGNODRN (Q1UE34:SAO) closed at 328.82, -2.85% below its 52-week high of 338.47, set on May 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 328.82 |
---|---|
High | 328.82 |
Low | 328.82 |
Bid | 347.40 |
Offer | 348.84 |
Previous close | 328.82 |
Average volume | -- |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Annual div (ADY) | 5.00 BRL |
---|---|
Annual div yield (ADY) | 1.52% |
Div ex-date | Apr 05 2024 |
Div pay-date | Apr 26 2024 |
Data delayed at least 15 minutes, as of May 02 2024 20:54 BST.
More ▼